Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone - Full Text View

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

This study is currently recruiting participants.
Verified by Atrium Medical Center, September 2005

Sponsored by:	Atrium Medical Center
Information provided by:	Atrium Medical Center
ClinicalTrials.gov Identifier:	NCT00206193

Purpose

The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Condition	Intervention	Phase
Abortion, Induced	Drug: mifepristone Drug: misoprostol Drug: sulprostone	Phase II

ChemIDplus related topics:

Mifepristone Misoprostol Sulprostone

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female

Criteria

Inclusion Criteria:

Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

Women with liver/kidney disease
Women on long-term use of corticosteroids (> 6 months)
Cardiovascular problems
Therapy-resistant diabetic women
Therapy-resistant asthma/bronchitis
Thalassemia
Ulcerative colitis
Peptic ulcer disease
Glaucoma
Porphyria
Allergic reaction to prostaglandin or mifepristone
Women with a prior caesarian section or women with contractions at the start of the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00206193

Contacts


Contact: Suzanne HW Vonken, Dr.	003145-5766666 ext 466825	svonken@gmail.com

Contact: F Roumen, Dr.	003145-5766666 ext 466509

Locations


Netherlands, Limburg
	Atrium Medisch Centrum	Recruiting
	Heerlen, Limburg, Netherlands
	Contact: Suzanne HW Vonken, Dr. 045-5766666(6825)
	Principal Investigator: Suzanne HW Vonken, Dr.

Sponsors and Collaborators

Atrium Medical Center

Investigators


Study Director:	F Roumen, Dr.	Atrium Medisch Centrum Heerlen

More Information

Study ID Numbers:	TOP-protocol
First Received:	September 13, 2005
Last Updated:	October 29, 2007
ClinicalTrials.gov Identifier:	NCT00206193
Health Authority:	United States: Food and Drug Administration

Keywords provided by Atrium Medical Center:

termination of pregnancy

Study placed in the following topic categories:

Misoprostol

Mifepristone

Abortion, Spontaneous

Sulprostone

Additional relevant MeSH terms:

Abortifacient Agents, Steroidal

Contraceptives, Postcoital, Synthetic

Oxytocics

Contraceptive Agents

Hormone Antagonists

Contraceptives, Oral

Physiological Effects of Drugs

Gastrointestinal Agents

Contraceptive Agents, Female

Hormones, Hormone Substitutes, and Hormone Antagonists

Reproductive Control Agents

Abortifacient Agents, Nonsteroidal

Contraceptives, Postcoital

Luteolytic Agents

Pharmacologic Actions

Therapeutic Uses

Anti-Ulcer Agents

Abortifacient Agents

Menstruation-Inducing Agents

Contraceptives, Oral, Synthetic

ClinicalTrials.gov processed this record on October 10, 2008